All Posts

25% lab vacancy rates are exposing operational design gaps The laboratory workforce crisis isn't going away — but the labs managing it best aren't just hiring harder. They're operating smarter.   The numbers are stark: pathologist supply is projected to decline 7% while demand grows 16% over the next decade. Lab vacancy rates are hovering near 25% nationally. Up to 60% of the MT/MLS workforce is approaching retirement age. These aren't projections anymore — they're showing up

DOJ's new AI tools are finding fraud before complaints are filed Compliance enforcement just got smarter — and most labs aren't keeping pace.   DOJ's Health Care Fraud Data Fusion Center now uses AI and advanced analytics to detect billing anomalies automatically — before complaints are filed, before audits are scheduled, and before labs know they're on the radar. High-utilization panels, unusual ordering patterns, geographic outliers, and unbundling trends are being flagged

$6.8B in FCA recoveries. Labs are a primary target. Is your program current? FY 2025 was a record year for healthcare fraud enforcement—and labs were a primary target.   The Department of Justice announced $6.8 billion in False Claims Act settlements and judgments, the highest annual total in the statute's history. Over $5.7 billion came from healthcare matters alone. Whistleblowers filed a record 1,297 qui tam lawsuits, and DOJ opened 401 new investigations. The message is c

National operators are acquiring hospital outreach at premium valuations. What's your lab outreach program really worth?   More health systems are asking this question as national operators acquire hospital outreach businesses at premium valuations. In 2025 alone, Labcorp signed or closed 13 health system outreach transactions—including the $195 million acquisition of Community Health Systems' outreach assets. Quest completed the acquisition of University Hospitals' outreach

FNA, Pap, and non-gyn coding errors quietly drain your bottom line Most labs are leaving cytology revenue on the table.   Cytology billing is one of the most complex areas of the lab revenue cycle. Whether it's gynecologic Pap tests, non-gyn specimens, or fine needle aspiration (FNA) procedures, the coding nuances create recurring problems—and the gap between correct and incorrect billing isn't just lost revenue. It's compliance risk.   CMS continues to tighten enforcement on

The labs that will thrive in 2026 are the ones planning for it now. Regulatory uncertainty, revenue pressure, and technology decisions are converging—and the margin for reactive decision-making is shrinking.   Congress just delayed PAMA cuts again through the Consolidated Appropriations Act of 2026, freezing CLFS rates at 2025 levels and pushing reductions of up to 15 percent to 2027–2029. But the reprieve comes with a new obligation: labs must now report 2025 private payer d

What would happen to your laboratory operations if your Administrative Lab Director left tomorrow? Unexpected retirements, health emergencies, career moves, or organizational restructuring can create gaps that immediately affect daily operations, compliance standing, and strategic momentum. The Leadership Challenge The laboratory workforce is experiencing a generational transition. According to ASCLS, more than 60% of laboratory professionals are approaching retirement age, w

PAMA cuts are currently scheduled to resume January 31, 2026—but if history is any guide, another delay remains possible.   Congress has intervened six consecutive times to postpone PAMA reimbursement cuts since 2020. The bipartisan RESULTS Act , introduced in September 2025, would freeze Clinical Laboratory Fee Schedule rates at current 2025 levels and cancel pending cuts through 2028. Industry advocacy through the "Stop Lab Cuts" campaign continues to push for passage.   Ho

Your 2026 laboratory budget is approved. The capital projects are funded. The service expansions are green-lit.   Now comes the hard part: making it happen.   Strategic plans only deliver value when they move into execution. Yet many laboratories struggle to translate approved initiatives into operational results—not because the strategy was flawed, but because execution lacks structure, accountability, and consistent oversight.   Where Execution Breaks Down 📋 Undefined acco

OIG enforcement is intensifying, and laboratories remain a primary focus.   False Claims Act settlements and judgments exceeded $6.8 billion in fiscal year 2025 —a record year. Laboratory-specific enforcement continues at a steady pace, with recent settlements involving kickback schemes, medically unnecessary testing, and improper referral arrangements resulting in multi-million dollar penalties and program exclusions.   For publicly traded laboratory companies, the complianc

The Challenge of Pathology Workflow Complexity Pathology and histology laboratories operate within some of the most complex workflows in the diagnostic space. Tissue handling, staining protocols, pathologist oversight, and quality monitoring all rely on systems that must be efficient, standardized, and continuously monitored for quality and compliance. Yet many pathology operations struggle with: Inconsistent specimen processing across multiple sites creating quality variabi

The Challenge of Growing Through Acquisition Health systems and physician groups continue expanding through mergers and acquisitions, but laboratory operations often remain disconnected. Separate LIS systems, fragmented EMR integrations, inconsistent reference lab contracts, and non-standardized protocols create hidden costs and missed opportunities.   The labs that thrive post-acquisition are those that approach consolidation strategically—not as a cost-cutting exercise, but

As we head toward the end of 2025, now is the right time to evaluate your compliance posture and enter 2026 with confidence. The Critical Window for Compliance Assessment Laboratory leaders across all settings—hospital core/outreach labs, independent commercial laboratories, physician office labs, and pathology/histology operations—understand that year-end is more than closing financial's. It's the opportunity to assess compliance readiness before regulatory agencies schedule